Clinuvel Pharmaceuticals Limited (CUVL)

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
Biopharmaceutical Sector	94.02M	95.02M	88.18M	78.32M	65.72M
Total	94.02M	95.02M	88.18M	78.32M	65.72M

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
Ireland	52.51M	46.21M	-	-	-
United States	40.73M	47.91M	-	-	-
Rest of The World	791.00K	903.00K	-	-	-
Switzerland and Others	-	-	6.70M	6.04M	5.58M
Europe & USA Excl. Switzerland	-	-	81.48M	72.28M	-
Europe and USA	-	-	-	-	60.14M
Total	94.02M	95.02M	88.18M	78.32M	65.72M

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 12, 2026

Data Sources Report a data error